Cadila Healthcare files NDA of Saroglitazar Mg with DCGI targeting liver diseases If the latest NDA is approved, Saroglitazar Mg could become the first medicine indicated for the treatment of Non-alcoholic Steatohepatitis (NASH).
Feedback
ZYDUSLIFE 
Reputation: 2,133 • Dec 6, 2019 12:54 AM
Vote
Comment
Share